Evolutionary conservation of the lipopolysaccharide binding site of β 2-glycoprotein I

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1069-1075

  Aǧar, Çetin ^a,b   de Groot, Philip G ^b   Marquart, J Arnoud ^a   Meijers, Joost C M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antiphospholipid syndrome; Inflammation; Protein function activity; Protein structure folding

Indexed keywords

ALANYLPHENYLALANYLTRYPTOPHANYLLYSYLTHREONYLASPARTYLALANINE; BETA2 GLYCOPROTEIN 1; CYSTYLLYSYLGLYCYLLYSYLGLUTAMYLLYSYLLYSYLCYSTEINE; EPITOPE; LEUCYLALANYLPHENYLALANYLTRYPTOPHANYLLYSYLTHREONYLASPARTYLALANINE; LIPOPOLYSACCHARIDE; PEPTIDE; PHOSPHOLIPID ANTIBODY; SERYLALANYLPHENYLALANINETRYPTOPHANYLLYSYLTHREONYLASPARTYLALANINE; THROMBOPLASTIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING COMPETITION; BINDING SITE; GENE SEQUENCE; GENETIC CONSERVATION; HUMAN; HYDROPHILICITY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; BETA 2-GLYCOPROTEIN I; BINDING SITES; BINDING, COMPETITIVE; CELLS, CULTURED; CONSERVED SEQUENCE; DOWN-REGULATION; EVOLUTION, MOLECULAR; HUMANS; LIPOPOLYSACCHARIDES; MOLECULAR SEQUENCE DATA; MONOCYTES; PEPTIDE FRAGMENTS; SEQUENCE ALIGNMENT; SURFACE PLASMON RESONANCE; THROMBOPLASTIN;

EID: 82555175368     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-05-0333     Document Type: Article

References (33)

1. Aǧar Ç, van Os GMA, Mörgelin, M, et al. Beta2-Glycoprotein I can exist in two conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-1343.
2. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-3644.
3. Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-5174.
4. Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-6239.
5. Brier AM, Snyderman R, Mergenhagen SE, et al. Inflammation and herpes simplex virus: release of a chemotaxis-generating factor from infected cells. Science 1970; 170: 1104-1106.
6. Pangburn MK, Rawal N. Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 2002; 30: 1006-1010.
7. Oosting JD, Derksen RH, Entjes HT, et al. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
8. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-2145.
9. Hunt JE, Krilis SA. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-659.
10. Aǧar Ç, de Groot PG, Mörgelin, M, et al. β2GPI; a novel component of innate immunity. Blood 2011; 117: 6939-47.
11. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
12. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124.
13. Ohkura N, Hagihara Y, Yoshimura T, et al. Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998; 91: 4173-4179.
14. van Zoelen MA, Bakhtiari K, Dessing MC, et al. Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells. Thromb Haemost 2006; 96: 789-793.
15. Altschul SF, Madden TL, Schäffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-3402.
16. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-7103.
17. de Laat B, Derksen RH, Urbanus RT, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-1545.
18. Ioannou Y, Pericleous C, Giles I. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 280-290.
19. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178.
20. Sellar GC, Steel DM, Zafiropoulos A, Seery LT, et al. Characterization, expression and evolution of mouse beta 2-glycoprotein I (apolipoprotein H). Biochem Biophys Res Commun 1994; 200: 1521-1528.
21. Tincani A, Spatola L, Prati E, et al. The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution. J Immunol 1996; 157: 5732-5738.
22. Hammel M, Schwarzenbacher R, Gries A, et al. Mechanism of the interaction of beta(2)-glycoprotein I with negatively charged phospholipid membranes. Biochemistry 2001; 40: 14173-14181.
23. Hong DP, Hagihara Y, Kato H, et al. Flexible loop of beta 2-glycoprotein I domain V specifically interacts with hydrophobic ligands. Biochemistry 2001; 40: 8092-8100.
24. Greinacher A. Opposites attract. Blood 2010; 115: 440-441.
25. Nomura S, Komiyama Y, Matsuura E, et al. Binding of beta 2-glycoprotein I to platelet- derived microparticles. Br J Haem 1993; 85: 639-640.
26. Chonn A, Semple SC, Cullis PR. Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self"particles. J Biol Chem 1995; 270: 25845-25849.
27. Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine- expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem 1997; 272: 31113-31117.
28. Reed JH, Giannakopoulos B, Jackson MW, et al. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum 2009; 60: 860-869.
29. Reed JH, Clancy RM, Purcell AW, et al {beta}2-Glycoprotein I and Protection from Anti-SSA/Ro60-Associated Cardiac Manifestations of Neonatal Lupus. J Immunol 2011; 187: 520-526.
30. Abdel-Monem H, Dasgupta SK, Le A, et al. Phagocytosis of platelet microvesicles and beta2-glycoprotein I. Thromb Haemost 2010; 104: 335-341.
31. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573.
32. Freire de Carvalho J, Sherer Y, Shoenfeld Y. The fine-tuning of anti-oxidized lowdensity lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost 2007; 98: 1157-1159.
33. Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41: 215-223.